Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer

• Published in: Cancer Vol. 126; no. 10; pp. 2139 - 2145
• Main Authors: Lee, Yeh Chen, Wang, Lisa, Kohn, Elise C., Rubinstein, Lawrence, Ivy, S. Percy, Harris, Pamela J., Lheureux, Stephanie
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 15.05.2020
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Cancer; Cancer therapies; Chemotherapy; clinical protocols; Clinical trials; Clinical Trials, Phase I as Topic; Databases, Factual; Demographics; Demography; drug therapy; Drug-Related Side Effects and Adverse Reactions - classification; Drug-Related Side Effects and Adverse Reactions - epidemiology; Female; Genital Neoplasms, Female - drug therapy; Health risks; Health services; Humans; Medical treatment; Middle Aged; Multiple regression models; National Cancer Institute (U.S.); Oncology; Ovarian cancer; ovarian neoplasms; Patients; Peritoneal diseases; Peritoneum; Radiation therapy; Regression analysis; Retrospective Studies; Surgery; Toxicity; United States; Young Adult; United States; toxicity; ovarian neoplasms; drug therapy; clinical protocols

Background Women with gynecologic cancer may be at increased risk for adverse events (AEs) due to peritoneal disease burden and prior treatment (surgery, chemotherapy, and pelvic radiotherapy). This study compared the toxicity profiles of patients with and without gynecologic cancer enrolled in phas...